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Background
We recently reported a direct, inverse, significant linear
correlation of Env divergence from our live-attenuated
vaccine strain (EIAVD9) and protection from disease. This
marked effect of Env variation or viral evolution on vac-
cine efficacy begged the current questions: what is the rela-
tionship of Env variation and viral evolution to vaccine
efficacy and does the evolution of virus in inapparent car-
riers differ from the evolution of attenuated vaccine
viruses? Hence we further examined this relationship of
Env divergence, evolution, and vaccine efficacy via inves-
tigations into Env evolution during inapparent infections,
the elimination of ancestral viral species in infected
ponies, and EIAVD9 day of challenge (DOC) evolution
association with vaccine protection.
Methods
To implement this study we first examined Env popula-
tions from an experimentally infected long-term inappar-
ent-carrier treated with dexamethasone to abrogate
immune control of infection and enhance replication of
viral quasispecies from reservoir tissues. Second, DOC
Env populations were examined from 24 outbred ponies
that were vaccinated with EIAVD9 and subsequently chal-
lenged with three challenge strains of increasing Env
divergence from the vaccine strain.
Results
Characterization of the inapparent-carrier populations
revealed only novel quasispecies distinct from all previous
populations. Comprehensive analysis of tissue and
plasma samples from immune suppressed carriers indi-
cated that the original infectious inoculum and early viral
populations were evidently eliminated. DOC sequence
analysis of EIAVD9 vaccinates demonstrated viral evolu-
tion, although at lower levels than observed with virulent
EIAV strains at 7 months post-infection. EIAVD9 evolu-
tion revealed a significant association with vaccine protec-
tion from disease.
Conclusion
Env evolution is a double-edged sword: in the context of
a live-attenuated vaccine strain it is associated with
increased protection from disease upon challenge. Con-
versely, while the host immune system is able to eliminate
a diverse array of variants, viral persistence is maintained
by a relentless evolution of new Env populations from tis-
sue reservoirs.
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